(Q31001545)

28 June 2017

A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data (English)

1 reference

28 June 2017

1 reference

Rachna Kasliwal

1

1 reference

28 June 2017

Deborah Layton

2

1 reference

28 June 2017

Scott Harris

3

1 reference

28 June 2017

Lynda Wilton

4

1 reference

28 June 2017

Saad A W Shakir

5

1 reference

28 June 2017

1 January 2005

1 reference

28 June 2017

1 reference

28 June 2017

28

1 reference

28 June 2017

9

1 reference

28 June 2017

803-816

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200528090-00005

28 June 2017

0 references

cites work

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

1 reference

12 December 2020

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

12 December 2020

Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data

1 reference

12 December 2020

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

12 December 2020

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

12 December 2020

Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme

1 reference

12 December 2020

Coxibs and cardiovascular disease

1 reference

12 December 2020

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

1 reference

12 December 2020

Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors

1 reference

12 December 2020

Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data

1 reference

12 December 2020

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

1 reference

12 December 2020

COX-2 selective inhibitors--important lessons learned

1 reference

12 December 2020

The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?

1 reference

12 December 2020

1 reference

12 December 2020

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

1 reference

12 December 2020

Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data

1 reference

12 December 2020

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension

1 reference

12 December 2020

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

12 December 2020

Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.

1 reference

12 December 2020

Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study

1 reference

12 December 2020

Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology

1 reference

12 December 2020

Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents.

1 reference

12 December 2020

Selective COX-2 inhibition improves endothelial function in coronary artery disease

1 reference

12 December 2020

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

1 reference

12 December 2020

COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study

1 reference

12 December 2020

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

12 December 2020

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

12 December 2020

Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study

1 reference

12 December 2020

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data

1 reference

12 December 2020

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

1 reference

12 December 2020

10.2165/00002018-200528090-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

28 June 2017

0 references

1 reference